Dexcom G7 Receives FDA Clearance
The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all Types of diabetes ages two years and older.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005302/en/
Dexcom G7 now offers a more powerful and easier to use system with a small, all-in-one wearable with no fingersticks or scanning required. (Photo: Business Wire)
Lesen Sie auch
“There’s a reason Dexcom has the best-selling real-time CGM on the market,” said Kevin Sayer, chairman, president and CEO of Dexcom. “For more than a decade, we’ve pioneered generation after generation of sensing technology that consistently delivers improved accuracy, reliability and a simpler user experience, giving people greater control of their diabetes. When we set out to design G7, our goal was simple: to make the most powerful, easy-to-use CGM available for people with diabetes, whether they have Type 1 or Type 2. G7 delivers squarely on that promise. And now that it has been cleared by the FDA, we look forward to making G7 commercially available in the coming months.”
New features with Dexcom G7:
|
Dexcom G6 features included with Dexcom G7: |